Glenn Eisenberg - Laboratory Chief Financial Officer, Executive Vice President
| LH Stock | USD 241.29 1.62 0.68% |
President
Mr. Glenn A. Eisenberg is Chief Financial Officer, Executive Vice President of the Company. Mr. Eisenberg received his Bachelor of Arts degree from Tulane University in 1982 and his MBA from Georgia State University in 1988. From 2002 until he joined the Company, he served as the Executive Vice President of Finance and Administration and Chief Financial Officer at The Timken Company, a 4.3 billion leading global manufacturer of highly engineered bearings and alloy steels and related products and services. Previously, he served as President and Chief Operating Officer of United Dominion Industries, now a subsidiary of SPX Corporationrationration, after working in several roles in finance, including Executive Vice President and Chief Financial Officer. Mr. Eisenberg serves on the Board of Directors of US Ecology, and he served on the Boards of Directors of Family Dollar Stores Inc. until July 2015, where he chaired the Audit Committee and Alpha Natural Resources Inc. until May 2015, where he was the lead independent director and chaired the Nominating and Corporationrationrate Governance Committee. since 2014.
| Age | 63 |
| Tenure | 10 years |
| Address | 358 South Main Street, Burlington, NC, United States, 27215 |
| Phone | 336 229 1127 |
| Web | https://www.labcorp.com |
Glenn Eisenberg Latest Insider Activity
Tracking and analyzing the buying and selling activities of Glenn Eisenberg against Laboratory stock is an integral part of due diligence when investing in Laboratory. Glenn Eisenberg insider activity provides valuable insight into whether Laboratory is net buyers or sellers over its current business cycle. Note, Laboratory insiders must abide by specific rules, including filing SEC forms every time they buy or sell Laboratory'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Glenn Eisenberg over three months ago Disposition of 9071 shares by Glenn Eisenberg of Laboratory at 224.5488 subject to Rule 16b-3 | ||
Glenn Eisenberg over three months ago Disposition of 18379 shares by Glenn Eisenberg of Laboratory at 215.3661 subject to Rule 16b-3 |
Laboratory Management Efficiency
The company has Return on Asset (ROA) of 0.0396 % which means that for every $100 of assets, it generated a profit of $0.0396. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0543 %, which means that it produced $0.0543 on every 100 dollars invested by current stockholders. Laboratory's management efficiency ratios could be used to measure how well Laboratory manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to 0.05. The current Return On Capital Employed is estimated to decrease to 0.05. As of now, Laboratory's Total Current Assets are increasing as compared to previous years. The Laboratory's current Other Assets is estimated to increase to about 531.7 M, while Non Currrent Assets Other are projected to decrease to under 270.8 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| William Fleming | Humana Inc | 53 | |
| James MBA | Humana Inc | 53 | |
| Marc Miller | Universal Health Services | 53 | |
| Jennifer Schneiders | Hologic | 56 | |
| Jan Verstreken | Hologic | 56 | |
| Amol Chaubal | Waters | 47 | |
| Michael Prevoznik | Quest Diagnostics Incorporated | 62 | |
| Steve Filton | Universal Health Services | 66 | |
| Bethanie Stein | Humana Inc | N/A | |
| Alan Wheatley | Humana Inc | 51 | |
| John III | Humana Inc | N/A | |
| Carrie Manner | Quest Diagnostics Incorporated | 45 | |
| Cynthia Zipperle | Humana Inc | 58 | |
| David Dintenfass | Humana Inc | N/A | |
| Catherine Doherty | Quest Diagnostics Incorporated | 61 | |
| Gabrielle Wolfson | Quest Diagnostics Incorporated | N/A | |
| Susan Diamond | Humana Inc | 50 | |
| Christopher Hunter | Humana Inc | 52 | |
| Michael Deppe | Quest Diagnostics Incorporated | 57 | |
| Elizabeth Rae | Waters | 60 | |
| Robert Carson | Waters | 46 | |
Management Performance
| Return On Equity | 0.0543 | ||||
| Return On Asset | 0.0396 |
Laboratory Leadership Team
Elected by the shareholders, the Laboratory's board of directors comprises two types of representatives: Laboratory inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Laboratory. The board's role is to monitor Laboratory's management team and ensure that shareholders' interests are well served. Laboratory's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Laboratory's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Akinbolade Oyegunwa, Executive Officer | ||
| Anita Graham, Executive Officer | ||
| Glenn Eisenberg, Chief Financial Officer, Executive Vice President | ||
| Lance Berberian, Executive Vice President, Chief Technology Officer, Chief Information Officer | ||
| Judith Seltz, Chief Human Resource Officer, Executive Vice President | ||
| Michelle Abelson, Laboratory Operations | ||
| Jonathan DiVincenzo, Executive International | ||
| Kerrii Anderson, Independent Director | ||
| JD MD, President EVP | ||
| Amy Summy, Executive Vice President Chief Marketing Officer | ||
| Mark Schroeder, Executive Vice President and Presidentident of Diagnostics Laboratory Operations and Global Supply Chain | ||
| Robert Pringle, Senior Treasurer | ||
| Peter Wilkinson, Senior Vice President, Chief Accounting Officer | ||
| Paul MD, Ex Devel | ||
| Marcia Eisenberg, Enterprise VP | ||
| John Treadwell, Vice Initiatives | ||
| Brian Caveney, Executive Vice President, President, Diagnostics and Chief Medical Officer | ||
| D Gilliland, Independent Director | ||
| JeanLuc Belingard, Independent Director | ||
| Sandra JD, Chief VP | ||
| Kathryn Wengel, Independent Director | ||
| Peter Neupert, Lead Independent Director | ||
| Paul Kirchgraber, Executive Vice President and Chief Executive Officer - Covance Drug Development | ||
| Richelle Parham, Independent Director | ||
| Robert Williams, Independent Director | ||
| Jeffrey Davis, Independent Director | ||
| Christin ODonnell, Vice Relations | ||
| Megan MPH, Executive Officer | ||
| Chas Cook, VP Relations | ||
| Deborah SesokPizzini, SVP Officer | ||
| Garheng Kong, Independent Director | ||
| Adam Schechter, Chairman of the Board, President, Chief Executive Officer | ||
| Sandra Vaart, Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | ||
| MPH MD, Pres VP |
Laboratory Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Laboratory a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0543 | ||||
| Return On Asset | 0.0396 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 26.25 B | ||||
| Shares Outstanding | 83.64 M | ||||
| Shares Owned By Insiders | 0.32 % | ||||
| Shares Owned By Institutions | 94.82 % | ||||
| Number Of Shares Shorted | 2.03 M | ||||
| Price To Earning | 12.69 X |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Laboratory. If investors know Laboratory will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Laboratory listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.05) | Dividend Share 2.88 | Earnings Share 5.27 | Revenue Per Share 151.028 | Quarterly Revenue Growth 0.074 |
The market value of Laboratory is measured differently than its book value, which is the value of Laboratory that is recorded on the company's balance sheet. Investors also form their own opinion of Laboratory's value that differs from its market value or its book value, called intrinsic value, which is Laboratory's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Laboratory's market value can be influenced by many factors that don't directly affect Laboratory's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Laboratory's value and its price as these two are different measures arrived at by different means. Investors typically determine if Laboratory is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Laboratory's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.